SYDRA

SYDRA pitch by Alexander Dakhovnik @ Aging Research & Drug Discovery Meeting 2024

A NEW #geroprotector discovered‼️ Ergothioneine improves healthspan of aged animals by enhancing cGPDH activity through CSE-dependent persulfidation #lifespan #longevity #aging #healthspan #mitochondria #energy

🏹 𝚃𝚒𝚖𝚎'𝚜 𝙰𝚛𝚛𝚘𝚠: 𝚃𝚑𝚎 𝙾𝚗𝚎 𝙲𝚘𝚗𝚜𝚝𝚊𝚗𝚝 𝚒𝚗 𝙻𝚘𝚗𝚐𝚎𝚟𝚒𝚝𝚢 𝚁𝚎𝚜𝚎𝚊𝚛𝚌𝚑 🔜 The quest to understand and extend healthy human lifespan faces a fundamental constraint that no technological advancement can overcome: the linear passage of time itself. While artificial intelligence promises to accelerate our understanding of aging's molecular mechanisms and help identify promising interventions, we must acknowledge that validating any longevity intervention requires patience measured in years, if not decades. Consider the paradox: We can now process vast datasets in seconds and simulate molecular interactions in minutes, yet we cannot compress the time needed to observe how these interventions actually influence lifespan and healthspan. A mouse aging study still requires two to three years. A human longitudinal study demands decades. This is not a limitation of our tools or intellect – it is inherent to studying complex biological systems as they age. The recent explosion in AI-driven aging research has generated tremendous excitement, and rightfully so. Machine learning can help us identify promising compounds, predict biological age, and understand the intricate dance of genes and proteins that orchestrate aging. But we must resist the temptation to mistake accelerated discovery for accelerated validation. This is not to diminish AI's transformative potential. Rather, it is a reminder that biological time moves at its own pace. Each cell division, each protein modification, each epigenetic change unfolds in real time. The complexity of aging – with its multiple hallmarks interacting across tissues and timescales – demands that we observe its progression and our attempts to modify it with appropriate temporal humility. Perhaps this enforced patience is itself valuable. It compels us to be thoughtful in selecting which interventions to test, knowing each experiment represents years of commitment. It reminds us that aging research is not just about extending lifespan, but understanding the fundamental nature of time's passage in biological systems. Just sayin' As we harness AI's power to accelerate discovery, let us embrace the unchangeable tempo of validation. In this partnership between rapid computation and gradual biological time, we may find the right balance between innovation and understanding that leads to meaningful advances in human longevity. The future of aging research lies not in circumventing time's arrow, but in using our increasingly powerful tools to extract maximum insight from each precious moment of observation. As we wait for our experiments to unfold, we can take comfort in knowing that this very waiting is itself an essential part of the scientific process. I live in 'real-world' of clinical medicine with all its messiness and complexity. Dominika Wilczok Eric Verdin Dr Jack Kreindler https://lnkd.in/gA-M2vXP

Use of epigenetic clocks in oldest old individuals? In 433 oldest-old predominantly Chinese (95.6%) and female (60.3%) individuals of the SG90 cohort, better physical and functional performance is associated with lower GrimAge2 (indicative of a lower biological age), a deoxyribonucleic acid (DNA) methylation (DNAm) clock. Studies investigating biological aging biomarkers in the oldest-old population are scarce. The GrimAge2 clock was originally established in much younger populations. Nevertheless, it exhibits strong associations with clinically meaningful phenotypes in the oldest old. This does not suggest that geriatricians should replace established assessments such as IADL and SPPB, but rather that we can now explore the biological underpinnings of functional and physical decline - gaining insights from the epigenome. https://lnkd.in/d_gfP2wG Our latest NUS Academy for Healthy Longevity publication by the Oxford University Press, marks an exciting step forward. Huge congratulations to Jian Hua Tay on his first PhD publication, as well as to the team: Weilan Wang, Lihuan Guan, Rajkumar Dorajoo, FENG Lei, Brian Kennedy, Yap-Seng CHONG, Woon-Puay Koh, Tze Pin Ng. A special thank you to the SG90 participants and their families to enable this work!

New #geroprotector #discovery 💡 #cinnamaldehyde #cinnamon anti-#aging #mtor-inhibition #celegans #lifespan #healthspan

The field of geroscience promises to extend healthspan by addressing the biological mechanisms of aging. However, the complexity of aging poses significant risks, as interventions may unintentionally cause harm over varying timescales. In the recently published Nature Comment, "Balancing the Promise and Risks of Geroscience Interventions," first author Alan Cohen, who gave a compelling presentation at our 2023 Symposium, alongside Executive Co-Director Mahdi Moqri, Vadim Gladyshev of our Scientific Advisory Board, and Prof. Luigi Ferrucci of the National Institute on Aging (NIA) and our Scientific Steering Committee, explores strategies to mitigate these risks. Unlike diseases that affect individual systems, aging stems from trade-offs across complex biological networks. This multifactorial nature makes it challenging to predict whether interventions provide net benefits or long-term harms, even with rigorous short-term testing frameworks. Surrogate biomarkers play a crucial role in evaluating geroprotective therapies. However, the authors argue that due to aging's inherent heterogeneity, these markers may fail to capture critical trade-offs, potentially leading to unforeseen consequences, as observed with therapies like antioxidant supplements. To address these challenges, the authors propose eight strategies, including prioritizing lifestyle interventions, developing safety biomarkers, and initially focusing on older cohorts. These approaches aim to balance benefits and risks across diverse populations and timescales. To ensure safety, interventions must demonstrate benefits across validated biomarkers and undergo extended trials. Public access should be limited initially to older adults, with a gradual rollout as more evidence accumulates over decades. Careful assessment and transparent communication are essential to realizing the potential of geroscience while avoiding harm. Read the full Comment article, made available through the Consortium: https://lnkd.in/eu9X54c4

End of year present for the longevity field: confirmation that metformin plays a significant role in aging in primates!

Thank you for this beautifully composed interview! Although I closed my academic lab, I still get up early every morning, inspired to solve the mystery of aging. I evolved to the next level of learning drug discovery to restore cell and tissue function in diseases of aging and apply regenerative medicine at Novartis Biomedical Research.

#brain #aging #biomarkers #proteins in #plasma 🤔

#gym #workout to slow down #aging #telomeres #gerontology #aging #sport #gym